Abstract
c-Met and RON are receptor tyrosine kinases (RTK) that are closely related, both from a homology as well as from a functional stand point. Both receptors can induce cell migration, invasion, proliferation and survival in response to their respective ligand. Moreover, both possess oncogenic activity in vitro, in animal models in vivo and are often deregulated in human cancers. c-Met attracted a lot of interest shortly after its discovery in the mid-1980s because of its unusual role in cell motility. Moreover, a causal role for c-Met activating mutations in human cancer propelled an intensive drug discovery effort throughout the research and pharmaceutical communities to find inhibitors of c-Met. While c-Met is now a well-accepted target for an anti-cancer drug, less is known about the role of RON in cancer. Interestingly, despite their many common attributes, c-Met and RON are activated by different mechanisms in cancer cells. Because of the homology between the two RTKs, some small molecule kinase inhibitors of c-Met have inhibitory activity on RON, opening the door to exploring the role of both receptors in human cancers. In this review we will discuss the relevance of both c-Met and RON deregulation in human cancers and the progress so far in identifying small molecule kinase inhibitors that can block the activity of these targets in vitro and lead to anti-tumor effects in animal models.
Keywords: c-Met, RON, kinase inhibitor, small molecule, cancer, crystal structure
Anti-Cancer Agents in Medicinal Chemistry
Title: From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Volume: 9 Issue: 2
Author(s): Isabelle Dussault and Steven F. Bellon
Affiliation:
Keywords: c-Met, RON, kinase inhibitor, small molecule, cancer, crystal structure
Abstract: c-Met and RON are receptor tyrosine kinases (RTK) that are closely related, both from a homology as well as from a functional stand point. Both receptors can induce cell migration, invasion, proliferation and survival in response to their respective ligand. Moreover, both possess oncogenic activity in vitro, in animal models in vivo and are often deregulated in human cancers. c-Met attracted a lot of interest shortly after its discovery in the mid-1980s because of its unusual role in cell motility. Moreover, a causal role for c-Met activating mutations in human cancer propelled an intensive drug discovery effort throughout the research and pharmaceutical communities to find inhibitors of c-Met. While c-Met is now a well-accepted target for an anti-cancer drug, less is known about the role of RON in cancer. Interestingly, despite their many common attributes, c-Met and RON are activated by different mechanisms in cancer cells. Because of the homology between the two RTKs, some small molecule kinase inhibitors of c-Met have inhibitory activity on RON, opening the door to exploring the role of both receptors in human cancers. In this review we will discuss the relevance of both c-Met and RON deregulation in human cancers and the progress so far in identifying small molecule kinase inhibitors that can block the activity of these targets in vitro and lead to anti-tumor effects in animal models.
Export Options
About this article
Cite this article as:
Dussault Isabelle and Bellon F. Steven, From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (2) . https://dx.doi.org/10.2174/187152009787313792
DOI https://dx.doi.org/10.2174/187152009787313792 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Editorial [Hot Topic: Immunotherapy of Cancer (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Image-Guided Photonic Energy Deposition for Cancer Ablation and Drug Delivery
Current Medical Imaging Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Nanomedicines as Therapeutics in HIV-AIDS
Pharmaceutical Nanotechnology Performance of Feature Selection Methods
Current Genomics Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions
Current Gene Therapy PET Imaging for Gene & Cell Therapy
Current Gene Therapy Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery)
Current Pharmaceutical Design Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds